Changing indications for invasive testing in an era of improved screening

Seminars in Perinatology

Volumn 40, Issue 1, 2016, Pages 56-66

  Norton, Mary E ^a   Rink, Britton D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mount Carmel Health Systems   (United States)

Author keywords

Amniocentesis; Chorionic villus sampling; Chromosomal microarray; Genetic counseling; Karyotype; Prenatal diagnosis

Indexed keywords

AMNIOCENTESIS; ANEUPLOIDY; CHORION VILLUS SAMPLING; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; DNA SEQUENCE; DOWN SYNDROME; FETUS ECHOGRAPHY; FETUS KARYOTYPING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; GENOTYPING TECHNIQUE; HETEROZYGOTE DETECTION; HUMAN; INFORMED CONSENT; INVASIVE PROCEDURE; MATERNAL AGE; MICROARRAY ANALYSIS; MOSAICISM; MULTIPLE PREGNANCY; NEXT GENERATION SEQUENCING; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; TRISOMY 21; FEMALE; FETUS BLOOD; KARYOTYPING; PREGNANCY; PROCEDURES; TRENDS;

AMNIOCENTESIS; CHORIONIC VILLI SAMPLING; FEMALE; FETAL BLOOD; GENETIC COUNSELING; GENETIC TESTING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84959178548     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2015.11.008     Document Type: Review

References (94)

1. Accessed 27.12.14. http://www.marchofdimes.org/baby/chromosomal-conditions.aspx.
2. Gardner R.J., Sutherland G.R. Chromosome Abnormalities and Genetic Counseling 2004, Oxford University Press, New York, NY. 3rd ed.
3. Nyberg D.A., Crane J.P. Chromosome abnormalities. Diagnostic Ultrasound of Fetal Anomalies: Text and Atlas 1990, 676-724. Year Book Medical, Chicago, IL. D.A. Nyberg, B.S. Mahony, D.H. Pretorius (Eds.).
4. Warburton D. De novo balanced chromosome rearrangements and extra marker chromosomes identified at prenatal diagnosis: clinical significance and distribution of breakpoints. Am J Hum Genet 1991, 49(5):995-1013.
5. Kuppermann M., Pena S., Bishop J.T., et al. Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial. J Am Med Assoc 2014, 312(12):1210-1217.
6. American College of Obstetricians and Gynecologists ACOG practice bulletin no. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007, 109(1):217-227.
7. American College of Obstetricians and Gynecologists ACOG practice bulletin no. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007, 110(6):1459-1467.
8. Norton M.E., Nakagawa S., Norem C., Gregorich S.E., Kuppermann M. Effects of changes in prenatal aneuploidy screening policies in an integrated health care system. Obstet Gynecol 2013, 121(2 Pt 1):265-271.
9. Gill S.K., Broussard C., Devine O., et al. Association between maternal age and birth defects of unknown etiology-United States, 1997-2007. Birth Defects Res A Clin Mol Teratol 2012, 94(12):1010-1018.
10. Warburton D., Dallaire L., Thangavelu M., et al. Trisomy recurrence: a reconsideration based on North American data. Am J Hum Genet 2004, 75(3):376-385.
11. Uehara S., Yaegashi N., Maeda T., et al. Risk of recurrence of fetal chromosomal aberrations: analysis of trisomy 21, trisomy 18, trisomy 13, and 45,X in 1,076 Japanese mothers. J Obstet Gynaecol Res 1999, 25(6):373-379.
12. De Souza E., Halliday J., Chan A., Bower C., Morris J.K. Recurrence risks for trisomies 13, 18, and 21. Am J Med Genet A 2009, 149A(12):2716-2722.
13. de Wit M.C., Srebniak M.I., Govaerts L.C., et al. Additional value of prenatal genomic array testing in fetuses with isolated structural ultrasound abnormalities and a normal karyotype: a systematic review of the literature. Ultrasound Obstet Gynecol 2014, 43(2):139-146.
14. Wapner R.J., Martin C.L., Levy B., et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012, 367(12):2175-2178.
15. Williamson R.A., Weiner C.P., Patil S., et al. Abnormal pregnancy sonogram: selective indication for fetal karyotype. Obstet Gynecol 1987, 69(1):15-20.
16. Wladimiroff J.W., Sachs E.S., Reuss A., et al. Prenatal diagnosis of chromosome abnormalities in the presence of fetal structural defects. Am J Med Genet 1988, 29(2):289-291.
17. Reddy U.M., Abuhamad A.Z., Leine D., Saade G.R. Fetal imaging. Executive Summary of a joint NICHD, SMFM, AIUM, ACOG,ACR,SPR, And SRU Fetal Imaging Workshop. Obstet Gyncol 2014, 123(4):1070-1082.
18. Tartaglia N.R., Howell S., Sutherland A., Wilson R., Wilson L. A review of trisomy X (47,XXX). Orphanet J Rare Dis 2010, 5:8. 10.1186/1750-1172-5-8.
19. Madureira C., Cunha M., Sousa M., et al. Treatment by testicular sperm extraction and intracytoplasmic sperm injection of 65 azoospermic patients with non-mosaic Klinefelter syndrome with birth of 17 healthy children. Andrology 2014, 2(4):623-631.
20. Burrello N., Vicari E., Calogero A.E. Chromosome abnormalities in spermatozoa of patients with azoospermia and normal somatic karyotype. Cytogenet Genome Res 2005, 111:363-365.
21. Pyott S.M., Pepin M.G., Schwarze U., et al. Recurrence of perinatal lethal osteogenesis imperfecta in sibships: parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance. Genet Med 2011, 13(2):125-130.
22. Jackson L.G., Zachary J.M., Fowler S.E., et al. A randomized comparison of transcervical and transabdominal chorionic-villus sampling. The U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group. N Engl J Med 1992, 327:594-598.
23. Akolekar R., Beta J., Picciarelli G., Ogilvie C., D'Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015, 45(1):16-26.
24. Muller F., Thibaud D., Poloce F., et al. Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers. Prenat Diagn 2002, 22:1036-1039.
25. Eddleman K.A., Malone F.D., Sullivan L., et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006, 108:1067-1072.
26. Odibo A.O., Gray D.L., Dicke J.M., et al. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year experience. Obstet Gynecol 2008, 111:589-595.
27. Tabor A., Vestergaard C.H., Lidegaard O. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 2009, 34:19-24.
28. Caughey A.B., Hopkins L.M., Norton M.E. Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. Obstet Gynecol 2006, 108:612-616.
29. Mazza V., Pati M., Bertucci E., et al. Age-specific risk of fetal loss post second trimester amniocentesis: analysis of 5,043 cases. Prenat Diagn 2007, 27:180-183.
30. Towner D., Currier R.J., Lorey F.W., Cunningham G.C., Greve L.C. Miscarriage risk from amniocentesis performed for abnormal maternal serum screening. Am J Obstet Gynecol 2007, 196(608):e1-e5.
31. Borgida A.F., Mills A.A., Feldman D.M., Rodis J.F., Egan J.F. Outcome of pregnancies complicated by ruptured membranes after genetic amniocentesis. Am J Obstet Gynecol 2000, 183:937-939.
32. Mennuti M.T., DiGaetano A., McDonnell A., Cohen A.W., Liston R.M. Fetal-maternal bleeding associated with genetic amniocentesis: real-time versus static ultrasound. Obstet Gynecol 1983, 62:26-30.
33. Romero R., Jeanty P., Reece E.A., et al. Sonographically monitored amniocentesis to decrease intraoperative complications. Obstet Gynecol 1985, 65:426-430.
34. Leschot N.J., Verjaal M., Treffers P.E. Risks of midtrimester amniocentesis; assessment in 3,000 pregnancies. Br J Obstet Gynaecol 1985, 92(8):804-807.
35. Kong C.W., Leung T.N., Leung T.Y., et al. Risk factors for procedure-related fetal losses after mid-trimester genetic amniocentesis. Prenat Diagn 2006, 26:925-930.
36. Nicolaides K., Brizot Mde L., Patel F., Snijders R. Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10-13 weeks' gestation. Lancet 1994, 344:435-439. [published erratum appears in: Lancet 1994;344:830].
37. Johnson J.M., Wilson R.D., Winsor E.J., et al. The early amniocentesis study: a randomized clinical trial of early amniocentesis versus midtrimester amniocentesis. Fetal Diagn Ther 1996, 11:85-93.
38. Sundberg K., Bang J., Smidt-Jensen S., et al. Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Lancet 1997, 350:697-703.
39. Canadian Early and Mid-trimester Amniocentesis Trial (CEMAT) Group Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet 1998, 351:242-247.
40. Yi W., Pan C.Q., Hao J., et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014, 60(3):523-529.
41. Ko T.M., Tseng L.H., Chang M.H., et al. Amniocentesis in mothers who are hepatitis B virus carriers does not expose the infant to an increased risk of hepatitis B virus infection. Arch Gynecol Obstet 1994, 255:25-30.
42. Delamare C., Carbonne B., Heim N., et al. Detection of hepatitis C virus RNA (HCV RNA) in amniotic fluid: a prospective study. J Hepatol 1999 Sep, 31(3):416-420.
43. Prasad M.R., Honegger J.R. Hepatitis C virus in pregnancy. Am J Perinatol 2013, 30(2):149-159.
44. Simões M., Marques C., Gonçalves A., et al. Amniocentesis in HIV pregnant women: 16 years of experience. Infect Dis Obstet Gynecol 2013, 2013:914272.
45. Alfirevic Z., Sundberg K., Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2003, (3):CD003252.
46. Odibo A.O., Dicke J.M., Gray D.L., et al. Evaluating the rate and risk factors for fetal loss after chorionic villus sampling. Obstet Gynecol 2008, 112:813-819.
47. Lau K.T., Leung Y.T., Fung Y.T., et al. Outcome of 1,355 consecutive transabdominal chorionic villus samplings in 1,351 patients. Chin Med J 2005, 118:1675-1681.
48. Silver R.K., MacGregor S.N., Sholl J.S., Hobart E.D., Waldee J.K. An evaluation of the chorionic villus sampling learning curve. Am J Obstet Gynecol 1990, 163:917-922. [Level III].
49. Wijnberger L.D., van der Schouw Y.T., Christiaens G.C. Learning in medicine: chorionic villus sampling. Prenat Diagn 2000, 20:241-246.
50. Kuliev A., Jackson L., Froster U., et al. Chorionic villus sampling safety. Report of World Health Organization/EURO meeting in association with the Seventh International Conference on Early Prenatal Diagnosis of Genetic Diseases, Tel-Aviv, Israel, May 21, 1994. Am J Obstet Gynecol 1996, 174:807-811.
51. Botto L.D., Olney R.S., Mastroiacovo P., et al. Chorionic villus sampling and transverse digital deficiencies: evidence for anatomic and gestational-age specificity of the digital deficiencies in two studies. Am J Med Genet 1996, 62:173-178.
52. Centers for Disease Control and Prevention Chorionic villus sampling and amniocentesis: recommendations for prenatal counseling. Morb Mortal Wkly Rep Recomm Rep 1995, 44(RR-9):1-12.
53. Bauland C.G., Smit J.M., Bartelink L.R., Zondervan H.A., Spauwen P.H. Hemangioma in the newborn: increased incidence after chorionic villus sampling. Prenat Diagn 2010, 30(10):913-917.
54. Bauland C.G., Smit J.M., Scheffers S.M., et al. Similar risk for hemangiomas after amniocentesis and transabdominal chorionic villus sampling. J Obstet Gynaecol Res 2012, 38(2):371-375.
55. Brambati B., Tului L. Prenatal genetic diagnosis through chorionic villus sampling. Genetic Disorders and the Fetus: Diagnosis, Prevention, and Treatment 2004, 179-213. Johns Hopkins University Press, Baltimore, MD. 5th ed. A. Milunsky (Ed.).
56. Philip J., Silver R.K., Wilson R.D., et al. Late first-trimester invasive prenatal diagnosis: results of an international randomized trial. Obstet Gynecol 2004, 103(6):1164-1173.
57. Tiller G.E., Kershberg H.B., Goff J., et al. Women's views and the impact of noninvasive prenatal testing on procedures in a managed care setting. Prenat Diagn 2014, 8. [Epub ahead of print]. 10.1002/pd.4495.
58. Chetty S., Garabedian M.J., Norton M.E. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013, 33(6):542-546.
59. Beamon C.J., Hardisty E.E., Harris S.C., Vora N.L. A single center's experience with noninvasive prenatal testing. Genet Med 2014, 16(9):681-687.
60. Wax J.R., Cartin A., Chard R., Lucas F.L., Pinette M.G. Noninvasive prenatal testing: impact on genetic counseling, invasive prenatal diagnosis, and trisomy 21 detection. J Clin Ultrasound 2015, 43(1):1-6.
61. Rose N.C., LaGrave D., Hafen B., Jackson M. The impact of utilization of early aneuploidy screening on amniocenteses available for training in obstetrics and fetal medicine. Prenat Diagn 2013, 233:242-244.
62. Canadian Collaborative CVS-Amniocentesis Clinical Trial Group Multicentre randomised clinical trial of chorion villus sampling and amniocentesis. First report. Lancet 1989, 1:1-6.
63. Rhoads G.G., Jackson L.G., Schlesselman S.E., et al. The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. N Engl J Med 1989, 320:609-617.
64. Meyers C., Adam R., Dungan J., Prenger V. Aneuploidy in twin gestations: when is maternal age advanced?. Obstet Gynecol 1997, 89:248-251.
65. Rodis J.F., Egan J.F., Craffey A., et al. Calculated risk of chromosomal abnormalities in twin gestations. Obstet Gynecol 1990, 76:1037-1041.
66. Boyle B., Morris J.K., McConkey R., et al. Prevalence and risk of Down syndrome in monozygotic and dizygotic multiple pregnancies in Europe: implications for prenatal screening. Br J Obstet Gynaecol 2014, 121(7):809-819.
67. Norton M.E., Wapner R.J., Kuppermann M., Jelliffe-Pawlowski L., Currier R.J. Cell free DNA analysis vs sequential screening as primary testing considering all fetal chromosomal abnormalities. Am J Obstet Gynecol 2015, 212:S2.
68. Librach C.L., Doran T.A., Benzie R.J., Jones J.M. Genetic amniocentesis in seventy twin pregnancies. Am J Obstet Gynecol 1984, 148:585-591.
69. Wapner R.J., Johnson A., Davis G., et al. Prenatal diagnosis in twin gestations: a comparison between second-trimester amniocentesis and first trimester chorionic villus sampling. Obstet Gynecol 1993, 82:49-56.
70. Cahill A.G., Macones G.A., Stamilio D.M., et al. Pregnancy loss rate after mid-trimester amniocentesis in twin pregnancies. Am J Obstet Gynecol 2009, 200(3):257.e1-257.e6.
71. Millaire M., Bujold E., Morency A.M., Gauthier R.J. Mid-trimester genetic amniocentesis in twin pregnancy and the risk of fetal loss. J Obstet Gynaecol Can 2006, 28(6):512-518.
72. van den Berg C., Braat A.P., Van Opstal D., et al. Amniocentesis or chorionic villus sampling in multiple gestations? Experience with 500 cases. Prenat Diagn 1999, 19:234-244.
73. Agarwal K., Alfirevic Z. Pregnancy loss after chorionic villus sampling and genetic amniocentesis in twin pregnancies: a systematic review. Ultrasound Obstet Gynecol 2012 Aug, 40(2):128-134.
74. Lee Y.M., Cleary-Goldman J., Thaker H.M., Simpson L.L. Antenatal sonographic prediction of twin chorionicity. Am J Obstet Gynecol 2006, 195:863-867.
75. Blumenfeld Y.J., Momirova V., Rouse D.J., et al. Accuracy of sonographic chorionicity classification in twin gestations. J Ultrasound Med 2014, 33(12):2187-2192.
76. Bianchi D.W., Parker R.L., Wentworth J., et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014, 370:799-808.
77. Zhu Y.J., Zheng Y.R., Li L., et al. Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis. J Matern Fetal Neonatal Med 2014, 27(18):1839-1844.
78. Flick A., Krakow D., Martirosian A., Silverman N., Platt L.D. Routine measurement of amniotic fluid alpha-fetoprotein and acetylcholinesterase: the need for a reevaluation. Am J Obstet Gynecol 2014, 211(2):139.e1-139.e6.
79. Miller D.T., Adam M.P., Aradhya S., et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010, 86(5):749-764.
80. American College of Obstetricians and Gynecologists Committee on Genetics Committee opinion no. 581: the use of chromosomal microarray analysis in prenatal diagnosis. Obstet Gynecol 2013, 122(6):1374-1377.
81. Reddy U.M., Page G.P., Saade G.R., et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. N Engl J Med 2012, 367(23):2185-2193.
82. Tepperberg J., Pettenati M.J., Rao P.N., et al. Prenatal diagnosis using interphase fluorescence in situ hybridization (FISH): 2-year multi-center retrospective study and review of the literature. Prenat Diagn 2001, 21:293-301.
83. Bryndorf T., Lundsteen C., Lamb A., Christensen B., Philip J. Rapid prenatal diagnosis of chromosome aneuploidies by interphase fluorescence in situ hybridization: a one-year clinical experience with high-risk and urgent fetal and postnatal samples. Acta Obstet Gynecol Scand 2000, 79:8-14.
84. Toutain J., Epiney M., Begorre M., et al. First-trimester prenatal diagnosis performed on pregnant women with fetal ultrasound abnormalities: the reliability of interphase fluorescence in situ hybridization (FISH) on mesenchymal core for the main aneuploidies. Eur J Obstet Gynecol Reprod Biol 2010, 149(2):143-146.
85. American College of Medical Genetics Technical and clinical assessment of fluorescence in situ hybridization: an ACMG/ASHG position statement. I. Technical considerations. Genet Med 2000, 2:356-361.
86. Yang Y., Muzny D.M., Reid J.G., et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Eng J Med 2013, 369:1502-1511.
87. Slavotinek A., Kaylor J., Pierce H., et al. CRB2 mutations produce a phenotype resembling congenital nephrosis, Finnish type, with cerebral ventriculomegaly and raised alpha-fetoprotein. Am J Hum Genet 2015, 96(1):162-169.
88. Goldberg J.D., Wohlferd M.M. Incidence and outcome of chromosomal mosaicism found at the time of chorionic villus sampling. Am J Obstet Gynecol 1997, 176(6):1349-1352. [discussion 1352-3].
89. Hahnemann J.M., Vejerslev L.O. European collaborative research mosaicism in CVS (EUCHROMIC)-fetal and extrafetal cell lineages in 192 gestations with CVS mosaicism involving single autosomal trisomy. Am J Med Genet 1997, 70(2):179-187.
90. Hsu L.Y.F., Yu M.-T., Richkind K.E., et al. Incidence and significance of chromosome mosaicism involving an autosomal structural abnormality diagnosed prenatally through amniocentesis: a collaborative study. Prenat Diagn 1996, 16(1):1-28.
91. Baffero G.M., Somigliana E., Crovetto F., et al. Confined placental mosaicism at chorionic villous sampling: risk factors and pregnancy outcome. Prenat Diagn 2012, 32(11):1102-1108.
92. Society for Maternal-Fetal Medicine, Berry S.M., Stone J., et al. Fetal blood sampling. Am J Obstet Gynecol 2013, 209(3):170-180.
93. Hsu L.Y., Benn P.A. Revised guidelines for the diagnosis of mosaicism in amniocytes. Prenat Diagn 1999, 19:1081-1082.
94. Clark S.L., DeVore G.R. Prenatal diagnosis for couples who would not consider abortion. Obstet Gynecol 1989, 73(6):1035-1037.